Prime Medicine Inc. (PRME) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, PRME scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 2/20 (ROIC -35%; FCF yield -17.58%), indicating that the business is consuming rather than generating cash relative to its market value. Whale 13F flow scores 17/20, reflecting institutional accumulation and options positioning, which is the strongest pillar and the main offsetting positive in the rating. Insider conviction scores 3/20 based on SEC Form 4 and Congressional PTR cluster flow, signaling weak insider-side support. Macro regime fit scores 7/20 with a beta of 1.0 and sector sensitivity. The forensic balance sheet scores 2/20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5), the second-weakest pillar and a direct flag on financial distress risk.

For a prospective investor, the upside case rests on institutional positioning and recent price momentum rather than on current cash generation or balance-sheet strength. The valuation tradeoff is stark: with operating margin at -60% and FCF yield at -17.58%, the equity has no current earnings or cash-flow support for its $950.4M market capitalization, so any thesis depends on future events not yet visible in reported results. The forensic readings (Altman Z 0.2, Piotroski F 3/9) point to elevated distress and deterioration risk. Taken together, the rating frames PRME as a high-risk, catalyst-dependent name where the composite signal is negative.

Prime Medicine Inc. (PRME) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, its market capitalization is $1.0B. Per the SEC financials, reported FY 2025 revenue was $4.6M against an operating loss of $-208.3M. The source data does not describe specific products, customers, or revenue mechanics beyond these figures.

Per the SEC financials, the company reported operating and net losses in each period shown, with cash declining from $182.5M in FY 2024 to $63.0M in FY 2025. Per the market data, gross margin is 0%, operating margin -60%, net margin -60%, and ROIC -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Those forensic readings, together with the cash decline, describe a weak balance-sheet posture.

Per the recent news feed, the headlines include a MARKET WIRE item on a roughly 26% one-month rally (YELLOW), a CATALYST item on a Citizens rating being maintained at Market Outperform (GREEN), a MARKET WIRE item on FDA trial wins (YELLOW), a RISK WATCH item on a 7.6% share decline (RED), a CATALYST item on a 23.2% surge (GREEN), and a MARKET WIRE chart-and-analysis page (YELLOW). The feed's mix of green, yellow, and red signals is mixed, with the single red item being a price-decline alert. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no supply-chain catalyst is identified in the source data.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated dependencies. A prospective investor should note that this absence is itself a data limitation rather than evidence of independence, since the graph contains no entries. Sector context is limited to the Health Care / Biological Products classification and the beta of 1.0 per the market data.

• What are the specific FY 2025 cash-burn drivers, and what is the current cash runway given the decline from $182.5M to $63.0M?
• What debt obligations sit behind the reported Debt/Equity of 0.5, given that the financials show debt as N/A?
• What clinical or regulatory milestones underlie the recent "FDA trial wins" coverage, and what is their timing?
• What analyst consensus, price targets, and insider or 13F holdings exist, given the analyst and holder sections are empty?
• What drove the reported EPS to show as N/A across all periods?